Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENX-104 PET Study in Healthy Volunteers
NCT07253272Phase 1Completed
- Sponsor
- Engrail Therapeutics
- Start
- Feb 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ENX-104 in major depressive disorder (MDD) and anhedonia ((none)), sponsored by Engrail Therapeutics. Primary endpoint: Number of Participants with Treatment Emergent Adverse Events. Started Feb 2025; status: completed.
02
Drugs
ENX-104
03
Conditions
major depressive disorder (MDD)anhedonia ((none))
Beyond the preview
Go deeper on NCT07253272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07253272.